Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Sodium Zirconium Cyclosilicate

What is Sodium Zirconium Cyclosilicate?

CAS No: 17141-74-1

Sodium Zirconium Cyclosilicate is an insoluble, non-absorbed inorganic material used as a potassium binder and a treatment for hyperkalemia. Upon administration as an oral suspension, sodium zirconium cyclosilicate selectively targets and binds to potassium in the gastrointestinal (GI) tract, exchanging its sodium ions for potassium ions. This increases fecal potassium excretion, decreases the concentration of free potassium in the GI lumen, and lowers serum potassium levels.

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

Sodium Zirconium Cyclosilicate is a named chemical or pharmaceutical-related substance. Its precise classification, grade, and intended use should be confirmed from the applicable technical documentation rather than inferred from the name alone. A toxicological assessment should evaluate reliable evidence for the specific material and consider its manufacturing and handling context, with assumptions and data gaps clearly documented.

A PDE or ADE sets a health-based limit on daily exposure to (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

The assessment for Sodium Zirconium Cyclosilicate should be reviewed when meaningful new toxicological data become available, the material's intended use or exposure route changes, manufacturing or handling conditions change, or relevant guidance is updated. A review may also be appropriate if new evidence changes the understanding of a critical effect. The reason for review and any resulting revisions should be documented through the applicable quality system.

An occupational exposure band for Sodium Zirconium Cyclosilicate can support preliminary hazard communication and control selection when a formal occupational exposure limit is unavailable or when a banding framework is used internally. However, an OEB is not automatically equivalent to a substance-specific OEL. The basis, uncertainty, and intended use of the band should be documented, and appropriate exposure controls should still be applied.

Published toxicity data can be limited for some substances. For Sodium Zirconium Cyclosilicate, the evaluator should identify the available evidence, assess its reliability, and document important gaps and assumptions. Relevant read-across or structure-based approaches may be considered when scientifically justified. Any resulting health-based limit should explain the reasoning and uncertainty clearly, and conclusions should not imply that missing data demonstrate an absence of hazard.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

An OEL assessment for Sodium Zirconium Cyclosilicate provides a health-based reference for evaluating occupational exposure. Employers can use it alongside exposure monitoring, process knowledge, engineering controls, containment, and appropriate work practices. The assessment should consider tasks such as dispensing, transfer, sampling, equipment cleaning, and maintenance, while recognizing that a numerical limit alone does not replace a complete occupational hygiene program.

If Sodium Zirconium Cyclosilicate is a biologic or macromolecular substance, its structural and functional characteristics may affect how the available evidence is interpreted. The assessment should consider relevant pharmacological activity, non-clinical and clinical information where available, and the handling context, including formulation, filling, transfer, and cleaning. The evaluator should use an evidence-based approach suited to the substance rather than automatically applying assumptions for small molecules.

A toxicological assessment of Sodium Zirconium Cyclosilicate helps identify relevant health hazards and provides a scientific basis for considering exposure limits and workplace precautions. Its findings can inform containment design, task procedures, exposure monitoring, personal protective equipment, and training as appropriate. Controls should reflect actual operations and exposure pathways, and the assessment should be used as part of a broader occupational hygiene program.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add (2R,4S)-2-Ethyl-6-(Trifluoromethyl)-1,2,3,4-Tetrahydroquinoline-4-Amine to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo